These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 31258325)

  • 1. A Comprehensive Review of Pegvaliase, an Enzyme Substitution Therapy for the Treatment of Phenylketonuria.
    Hydery T; Coppenrath VA
    Drug Target Insights; 2019; 13():1177392819857089. PubMed ID: 31258325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up.
    Burton BK; Longo N; Vockley J; Grange DK; Harding CO; Decker C; Li M; Lau K; Rosen O; Larimore K; Thomas J;
    Mol Genet Metab; 2020 Aug; 130(4):239-246. PubMed ID: 32593547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM).
    Thomas J; Levy H; Amato S; Vockley J; Zori R; Dimmock D; Harding CO; Bilder DA; Weng HH; Olbertz J; Merilainen M; Jiang J; Larimore K; Gupta S; Gu Z; Northrup H;
    Mol Genet Metab; 2018 May; 124(1):27-38. PubMed ID: 29653686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria.
    Zori R; Thomas JA; Shur N; Rizzo WB; Decker C; Rosen O; Li M; Schweighardt B; Larimore K; Longo N
    Mol Genet Metab; 2018 Nov; 125(3):217-227. PubMed ID: 30146451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegvaliase: a novel treatment option for adults with phenylketonuria.
    Mahan KC; Gandhi MA; Anand S
    Curr Med Res Opin; 2019 Apr; 35(4):647-651. PubMed ID: 30247930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study.
    Longo N; Zori R; Wasserstein MP; Vockley J; Burton BK; Decker C; Li M; Lau K; Jiang J; Larimore K; Thomas JA
    Orphanet J Rare Dis; 2018 Jul; 13(1):108. PubMed ID: 29973227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegvaliase: Immunological profile and recommendations for the clinical management of hypersensitivity reactions in patients with phenylketonuria treated with this enzyme substitution therapy.
    Hausmann O; Daha M; Longo N; Knol E; Müller I; Northrup H; Brockow K
    Mol Genet Metab; 2019; 128(1-2):84-91. PubMed ID: 31375398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-year interim safety and efficacy of pegvaliase in Japanese adults with phenylketonuria.
    Ishige M; Ito T; Hamazaki T; Kuwahara M; Lee L; Shintaku H
    Mol Genet Metab; 2023 Nov; 140(3):107697. PubMed ID: 37717412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achieving efficacy in subjects with sustained pegvaliase-neutralizing antibody responses.
    Aryal M; Lau K; Boyer R; Zhou H; Abend J; Gu K; Olbertz J; Gupta S; Zoog S; Larimore K
    Mol Genet Metab; 2021 Nov; 134(3):235-242. PubMed ID: 34716085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term comparative effectiveness of pegvaliase versus standard of care comparators in adults with phenylketonuria.
    Zori R; Ahring K; Burton B; Pastores GM; Rutsch F; Jha A; Jurecki E; Rowell R; Harding C
    Mol Genet Metab; 2019; 128(1-2):92-101. PubMed ID: 31439512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial.
    Harding CO; Amato RS; Stuy M; Longo N; Burton BK; Posner J; Weng HH; Merilainen M; Gu Z; Jiang J; Vockley J;
    Mol Genet Metab; 2018 May; 124(1):20-26. PubMed ID: 29628378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegvaliase therapy for phenylketonuria: Real-world case series and clinical insights.
    Scala I; Brodosi L; Gueraldi D; Manti F; Rovelli V; Zuvadelli J; Agnelli G; Cazzorla C; Nardecchia F; Giammanco A; Biasucci G
    Mol Genet Metab; 2024 May; 142(1):108151. PubMed ID: 38522180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First successful outcomes of pegvaliase (PALYNZIQ) in children.
    Alfadhel M; Albarakati R
    BMC Med Genomics; 2024 Mar; 17(1):76. PubMed ID: 38515136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating change in diet with pegvaliase treatment in adults with phenylketonuria: Analysis of phase 3 clinical trial data.
    Rohr F; Burton B; Dee A; Harding CO; Lilienstein J; Lindstrom K; MacLeod E; Rose S; Singh R; van Calcar S; Whitehall K
    Mol Genet Metab; 2024 Mar; 141(3):108122. PubMed ID: 38184920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegvaliase for the treatment of phenylketonuria: Final results of a long-term phase 3 clinical trial program.
    Harding CO; Longo N; Northrup H; Sacharow S; Singh R; Thomas JA; Vockley J; Zori RT; Bulloch Whitehall K; Lilienstein J; Lindstrom K; Levy DG; Jones S; Burton BK
    Mol Genet Metab Rep; 2024 Jun; 39():101084. PubMed ID: 38694233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of pegvaliase in the management of phenylketonuria: Case series of early experience in US clinics.
    Adams D; Andersson HC; Bausell H; Crivelly K; Eggerding C; Lah M; Lilienstein J; Lindstrom K; McNutt M; Ray JW; Saavedra H; Sacharow S; Starin D; Tiffany-Amaro J; Thomas J; Vucko E; Wessenberg LB; Whitehall K
    Mol Genet Metab Rep; 2021 Sep; 28():100790. PubMed ID: 34430209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegvaliase dose escalation to 80 mg daily may lead to efficacy in patients who do not exhibit an optimal response at lower doses.
    Vucko ER; Havens KE; Baker JJ; Burton BK
    Mol Genet Metab Rep; 2022 Sep; 32():100905. PubMed ID: 36046394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palynziq clinic: One year and 43 patients later.
    Lah M; McPheron M
    Mol Genet Metab; 2021 Jul; 133(3):250-256. PubMed ID: 34074593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenylalanine ammonia lyase (PAL): From discovery to enzyme substitution therapy for phenylketonuria.
    Levy HL; Sarkissian CN; Scriver CR
    Mol Genet Metab; 2018 Aug; 124(4):223-229. PubMed ID: 29941359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nutrition management of PKU with pegvaliase therapy: update of the web-based PKU nutrition management guideline recommendations.
    Cunningham A; Rohr F; Splett P; Mofidi S; Bausell H; Stembridge A; Kenneson A; Singh RH
    Orphanet J Rare Dis; 2023 Jun; 18(1):155. PubMed ID: 37349772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.